Divisions of Endocrinology, Metabolism, and Diabetes, Thyroid Center, Department of Internal Medicine, Faculty of Medicine, Universitas Syiah Kuala (University Syiah Kuala), Banda Aceh, Indonesia.
Divisions of Endocrinology, Metabolism, and Diabetes, Department of Internal Medicine, Dr. Zainoel Abidin Hospital, Banda Aceh, Indonesia.
Endocrinol Metab (Seoul). 2024 Aug;39(4):603-614. doi: 10.3803/EnM.2024.1987. Epub 2024 Aug 1.
Both Graves' disease (GD) and Hashimoto's thyroiditis (HT) are classified as autoimmune thyroid diseases (AITDs). It has been hypothesized that changes in the thyroid-stimulating hormone receptor (TSHR) gene may contribute to the development of these conditions. This study aimed to analyze the correlation between the TSHR rs179247 gene polymorphism and susceptibility to AITD.
We conducted a thorough search of the Google Scholar, Scopus, Medline, and Cochrane Library databases up until March 2, 2024, utilizing a combination of relevant keywords. This review examines data on the association between TSHR rs179247 and susceptibility to AITD. Random-effect models were employed to assess the odds ratio (OR), and the findings are presented along with their respective 95% confidence intervals (CIs).
The meta-analysis included 12 studies. All genetic models of the TSHR rs179247 gene polymorphism were associated with an increased risk of developing GD. Specifically, the associations were observed in the dominant model (OR, 1.65; P<0.00001), recessive model (OR, 1.65; P<0.00001), as well as for the AA genotype (OR, 2.09; P<0.00001), AG genotype (OR, 1.39; P<0.00001), and A allele (OR, 1.44; P<0.00001). Further regression analysis revealed that these associations were consistent regardless of the country of origin, sample size, age, and sex distribution. However, no association was found between TSHR rs179247 and the risk of HT across all genetic models.
This study suggests that the TSHR rs179247 gene polymorphism is associated with an increased risk of GD, but not with HT, and may therefore serve as a potential biomarker.
Graves 病（GD）和桥本甲状腺炎（HT）均被归类为自身免疫性甲状腺疾病（AITD）。有人假设，促甲状腺激素受体（TSHR）基因的变化可能导致这些疾病的发生。本研究旨在分析 TSHR rs179247 基因多态性与 AITD 易感性之间的相关性。
我们在 2024 年 3 月 2 日前，通过使用相关关键词，全面搜索了 Google Scholar、Scopus、Medline 和 Cochrane Library 数据库。本综述研究了 TSHR rs179247 与 AITD 易感性之间的关联数据。我们采用随机效应模型评估比值比（OR），并给出相应的 95%置信区间（CI）。
荟萃分析纳入了 12 项研究。TSHR rs179247 基因多态性的所有遗传模型均与 GD 发病风险增加相关。具体而言，在显性模型（OR，1.65；P<0.00001）、隐性模型（OR，1.65；P<0.00001）、AA 基因型（OR，2.09；P<0.00001）、AG 基因型（OR，1.39；P<0.00001）和 A 等位基因（OR，1.44；P<0.00001）中均观察到了这种关联。进一步的回归分析表明，这些关联在不论起源国、样本量、年龄和性别分布的情况下均一致。然而，在所有遗传模型中，均未发现 TSHR rs179247 与 HT 风险之间存在关联。
本研究表明，TSHR rs179247 基因多态性与 GD 发病风险增加相关，但与 HT 无关，因此可能成为一个潜在的生物标志物。
